Results
Extracorporeal membrane oxygenation (ECMO) can be lifesaving in patients
with severe forms of ARDS, or refractory cardio-circulatory compromise.
The Impella RP can provide right ventricular circulatory support for
patients who develop right side ventricular failure or decompensation
caused by COVID-19 complications, including pulmonary embolus. HT are
reserved for only those patients with a high short-term mortality. LVAD
as a bridge to transplant may be a viable strategy to get at-risk
patients home quickly. Elective LVAD implantations have been reduced and
only patients classified as INTERMACS profile 1 and 2 are being
considered for LVAD implantation. Delayed recognition of LVAD‐related
complications, misdiagnosis of COVID‐19, and impaired social and
psychological well‐being for patients and families may ensue. Remote
patient care with virtual or telephone contacts is becoming the norm.